A 35-year-old man of Chinese ethnicity presented to the emergency department with fever, rash, mouth pain and visual impairment after two weeks of therapy with allopurinol. On examination, the patient had a generalized maculopapular rash, orolabial ulceration (Figure 1), keratoconjunctivitis with pseudomembrane formation (Figure 2) and urethritis. He was given intravenous immunoglobulin for five days and cyclosporin for 14 days, and the allopurinol was discontinued. A skin biopsy later showed dermo-epidermal separation and a dermal lymphocytic infiltrate, consistent with overlapping Stevens–Johnson syndrome and toxic epidermal necrolysis.

The rash, oral mucositis and urethritis resolved completely after two weeks of therapy. After 18 months, the patient still had visual impairment and dry eye from corneal ulceration for which he was continuing to receive treatment with topical corticosteroids, cyclosporin, vitamin A and lubricants. Genotyping showed the presence of the human leukocyte antigen (HLA) allele-B*5801, which has been shown to have a strong association with allopurinol-induced hypersensitivity, especially among Han Chinese.1

Genetic susceptibility

This scenario shows the potential role for genetic screening to identify patients at risk for severe cutaneous adverse drug reactions. These reactions are life-threatening and idiosyncratic, and include overlapping Stevens–Johnson syndrome and toxic epidermal necrolysis, as well as drug-induced hypersensitivity syndrome (also known as drug reaction with eosinophilia and systemic symptoms, or DRESS).

Stevens–Johnson syndrome and toxic epidermal necrolysis are considered two forms of the same disease. They are distinguished arbitrarily by the extent of epidermal detachment (i.e., less than 10% in Stevens–Johnson syndrome, 10%–30% in overlapping Stevens–Johnson syndrome and toxic epidermal necrolysis, and greater than 30% in toxic epidermal necrolysis).3 Blistering erosions of the skin and mucous membranes result from apoptosis of keratinocytes.3 The reaction usually begins one to three weeks after treatment is started.4 Incidence of overlapping Stevens–Johnson syndrome and toxic epidermal necrolysis is emerging from Southeast Asia.5

Key points

1. Evidence is emerging of strong genetic predisposition to severe cutaneous adverse drug reactions, such as Stevens–Johnson syndrome and drug-induced hypersensitivity syndrome.
2. The human leukocyte antigen (HLA) allele-B*1502 confers a very high risk of carbamazepine-induced Stevens–Johnson syndrome among people of southeastern Asian ethnicity.
3. The United States Food and Drug Administration and Health Canada advise screening for HLA-B*1502 in patients of southeastern Asian ethnicity before carbamazepine therapy.
4. HLA-B*5801 confers a risk of allopurinol-induced severe cutaneous reactions among people of various ethnicities, but pretreatment screening is not readily available.
toxic epidermal necrolysis is low and estimated to be one to two patients per million inhabitants per year.5 Mortality, however, is high at 10% for Stevens–Johnson syndrome and 50% for toxic epidermal necrolysis.5

Drug-induced hypersensitivity syndrome is also a rare but potentially fatal reaction. The syndrome is characterized by fever, rash, lymphadenopathy, hepatitis and leukocyte abnormalities that may be triggered and perpetuated by herpes viruses such as HHV-6.7

Recent advances in genomic research have lead to the identification of genes that confer susceptibility to severe cutaneous adverse drug reactions, which appear to be specific to drug, phenotype and ethnicity. More than 100 drugs have been implicated as possible causes of Stevens–Johnson syndrome, toxic epidermal necrolysis and drug-induced hypersensitivity syndrome, but most such reactions are confined to a small number of agents (Boxes 1 and 2).

The most commonly offending drugs vary among different ethnic populations. In Western countries, the most commonly implicated agents of overlapping Stevens–Johnson syndrome and toxic epidermal necrolysis are nonsteroidal anti-inflammatory drugs (NSAIDs) and sulphonamides.8 By contrast, carbamazepine is the leading cause of Stevens–Johnson syndrome in Southeast Asian countries, including India, Malaysia, Singapore, Taiwan and Hong Kong.9 Carbamazepine in Western countries causes more instances of drug-induced hypersensitivity syndrome than overlapping Stevens–Johnson syndrome and toxic epidermal necrolysis. Allopurinol is also a frequent cause of overlapping Stevens–Johnson syndrome and toxic epidermal necrolysis and of drug-induced hypersensitivity syndrome, but it does not appear to have an ethnic bias.10

### HLA-B*1502 and carbamazepine

The most striking genetic association was detected in a cohort of Han Chinese in Taiwan, where the HLA-B*1502 allele was found in 100% of people with carbamazepine-induced overlapping Stevens–Johnson syndrome and toxic epidermal necrolysis, and only 3% of carbamazepine-tolerant people.11 These findings were replicated in an extended cohort of participants of Chinese descent originating from separated geographic areas (China, Taiwan, and the United States).12 However, this association with carbamazepine-induced overlapping Stevens–Johnson syndrome and toxic epidermal necrolysis was not found among people with European ancestry. The allele therefore appears relevant in the context of ethnicity.13

If an allele has a functional effect that may play a role in the pathogenesis of disease, this association will be consistently observed across different populations. The differences observed between the Chinese and European studies may be partly explained by the fact that pharmacogenetic studies are likely to yield positive results when conducted in a population with a high frequency of such an allele.14 The HLA-B*1502 allele frequency is 4.8%–12.8% in Southeast Asians compared with 0%–0.1% observed in white people (Figure 3A).14 The risk of disease from a genetic polymorphism is influenced by its prevalence. For instance, HLA-B*1502 has a low prevalence among Caucasians. If it is a true susceptibility allele, a very large sample size is required in this population to detect a significant odds ratio of sufficient power. Such studies have not been conducted to date. This fact may explain the low incidence of carbamazepine-induced Stevens–Johnson syndrome in non-Southeast Asians.

Plausibly, Stevens-Johnson syndrome may be a polygenic disorder, with many susceptibility and protective alleles

---

**Box 1: The main causative drugs of Stevens–Johnson syndrome**
- Sulphonamides
- Oxicam NSAIDs (e.g., piroxicam, meloxicam, tenoxicam)
- Carbamazepine
- Allopurinol
- Aminopenicillins
- Phenytoin
- Phenobarbital
- Nevirapine
- Lamotrigine

**Box 2: The main causative drugs of drug-induced hypersensitivity syndrome**
- Carbamazepine
- Phenytoin
- Phenobarbital
- Zonisamide
- Lamotrigine
- Allopurinol
- Dapsone
- Salazosulfapyridine
- Mexiletine
- Minocycline
- Abacavir
- Nevirapine
Figure 3: Approximate prevalence of the human leukocyte antigen (HLA) alleles HLA-B*1502 (A) and HLA-B*5801 (B) in various geographic regions of the world. Unshaded areas represent regions where prevalence of the gene has not been determined. From Middleton D, Menchaca L, Rood H, et al. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 2003;61:403-7.
in genes involved in the pathogenesis of the disease. Polymorphisms in the proapoptotic gene Fas-L,\textsuperscript{24} the toll-like receptor 3 gene\textsuperscript{25} and the IL-4 receptor/IL-13 signaling pathway\textsuperscript{26} have all been described recently in a Japanese study. Such alleles may vary in different populations.

Another explanation is that HLA-B*1502 is a marker of a true disease-contributing allele through strong linkage disequilibrium, which varies between populations. In other words, the same high-risk allele may have a different pattern of association with marker alleles and therefore HLA-B*1502 is in strong linkage disequilibrium in the Han Chinese population, but not in a European population.

Health Canada and the United States Food and Drug Administration (FDA) have issued warnings for carbamazepine, stating that persons with ancestry in genetically at-risk populations should be screened for the presence of HLA-B*1502 before initiating treatment.\textsuperscript{18,19} Genetic screening for HLA-B*1502 in a high-risk population such as the Han Chinese has a 100% sensitivity and 97% specificity and its presence confers a 7.7% positive predictive value for carbamazepine-induced overlapping Stevens–Johnson syndrome and toxic epidermal necrolysis, whereas its absence has a 100% negative predictive value.\textsuperscript{9} The odds ratio of carbamazepine-induced overlapping Stevens–Johnson syndrome and toxic epidermal necrolysis in test-positive Chinese patients to test-negative patients is > 3200. In 3% of patients who are test-positive, the disease may never develop with exposure to carbamazepine. However, the exclusion of carbamazepine use for all patients found to be test-positive is justified by the serious and life-threatening consequences of overlapping Stevens–Johnson syndrome and toxic epidermal necrolysis and by the availability of alternative drugs. The lack of prevalence of HLA-B*1502 in non-Asian populations may limit the cost-effectiveness of its use as a screening tool in these populations and therefore it cannot be recommended currently.

Many laboratories have now developed high-resolution genetic testing using a sequence-specific primer assay for the detection of this allele from samples collected in either 7–10 ml of whole blood (in an ethylenediamine tetra-acetate tube) or buccal swabs (provided by the testing laboratory). Results are usually available in seven days. Such a strategy is not novel and has been successful in virtually abolishing the use of this highly specialized and relatively expensive diagnostic technique is limited to a small number of laboratories that focus on transplantation medicine and may have longer turnaround times (i.e., up to three to four weeks).

Given the strong association of HLA-B*5801 with hypersensitivity to allopurinol across different ethnic populations (i.e., Southeast Asian, Japanese, European), screening all patients before therapy would be prudent. However, rapid methods of detection, as for HLA-B*5701 and HLA-B*1502, need to be readily available.

A hypothesis of drug accumulation has been suggested to explain the 4.7-fold increase in incidence of allopurinol-induced severe cutaneous drug reactions in renal insufficiency. However, adjusting the dosage of allopurinol did not significantly reduce hypersensitivity reactions.\textsuperscript{1,25}

**Pathogenesis of Stevens–Johnson syndrome**

The association of HLA genotypes with drug hypersensitivity also provides insight into the immune-mediated pathogenesis of overlapping Stevens–Johnson syndrome and toxic epidermal necrolysis. The strong association with HLA-B molecules suggests that they play a direct role in its development. A specific HLA-B molecule may present the drug or its metabolites to naive CD8 cells. The result may be clonal expansion of CD8 cytotoxic lymphocytes and induction of cytotoxic effector responses, resulting in apoptosis of keratinocytes. This process may occur through degranulation of perforin and granzyme B, and Fas-FasL interaction.\textsuperscript{24}

These pathways are not specific to overlapping Stevens–Johnson syndrome and toxic epidermal necrolysis. They are also upregulated in non-apoptotic drug-induced conditions such as maculopapular exanthema.\textsuperscript{21} Recently, Chung and colleagues reported that granulysin, a cytolytic protein released from CD8 cells, is present in blister fluid from patients with Stevens–Johnson syndrome at much greater concentrations than perforin or Fas-L.\textsuperscript{26} The correlation of levels of this protein with disease severity and the measurement of granulysin in blister fluid may be useful in monitoring disease progression.

**Conclusion**

Certain HLA-B molecules are associated with severe cutaneous adverse drug reactions, and these associations may be specific to drug, phenotype and ethnicity. To minimize the
high morbidity and mortality associated with severe cutaneous adverse drug reactions, genetic screening is advisable for at-risk groups (i.e., for HLA-B*1502 before carbamazepine therapy in patients of Southeastern Asian ethnicity and for HLA-B*5801 before allopurinol therapy in patients of Southeast Asian, Japanese and European ethnicities).

Given the large representation of these high-risk groups in Canada and the common prescription of these drugs, further measures need to be taken to minimize the occurrence of these severe and potentially life-threatening reactions. Such measures should include promoting awareness of risk and improving cost-effective screening methods and their availability. The low prevalence of these alleles in other ethnic populations and their lack of association with severe cutaneous adverse drug reactions in other ethnic populations suggest that this strategy would not be cost-effective for predicting such reactions in groups not at high risk. Whether screening for other alleles in these groups should be done in the future remains to be determined by case studies or genome-wide linkage studies.

This article has been peer reviewed.

Competing interests: None declared.

Contributors: Both of the authors were involved in the conception and development and the drafting of the article. Both critically revised it for important intellectual content and approved the final version submitted for publication.

REFERENCES


Correspondence to: Dr. Suran Fernando, Department of Clinical Immunology and Allergy, Royal North Shore Hospital, Reserve Rd., St. Leonards, Sydney NSW 2065 Australia; fax 61-2-9439-2798; sfernando@nscachs.health.nsw.gov.au

The section Cases presents brief case reports that convey clear, practical lessons. Preference is given to common presentations of important rare conditions, and important unusual presentations of common problems. Articles start with a case presentation (500 words maximum), and a discussion of the underlying condition follows (1000 words maximum). Generally, up to 5 references are permitted and visual elements (e.g., tables of the differential diagnosis, clinical features or diagnostic approach) are encouraged. Written consent from patients for publication of their story is a necessity and should accompany submissions. See information for authors at www.cmaj.ca.